Literature DB >> 28362408

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues.

József Murányi1, Attila Varga2, Bianka Gurbi2, Pál Gyulavári2, Gábor Mező3, Tibor Vántus4.   

Abstract

GnRH analogues are effective targeting moieties and able to deliver anticancer agents selectively into malignant tumor cells which highly express GnRH receptors. However, the quantitative analysis of GnRH analogues' cellular uptake and the investigated cell types in GnRH-based drug delivery systems are currently limited. Previously introduced, selectively labeled fluorescent GnRH I, -II and -III derivatives provide great detectability, and they have suitable chemical properties for reproducible and robust experiments. We also found that the appropriate up-to-date methods with these labeled GnRH analogues could offer novel information about the GnRH-based drug delivery systems. This manuscript introduces some simple and fast experiments regarding the cellular uptake of [D-Lys6(FITC)]-GnRH-I, [D-Lys6(FITC)]-GnRH-II and [Lys8(FITC)]-GnRH-III on the EBC-1 (lung), the BxPC-3 (pancreas) and on the Detroit-562- (pharynx) malignant tumor cells. In parallel with these GnRH-FITC conjugates, the cell surface level of GnRH-I receptors was also examined on these cell lines before and after the GnRH treatment by confocal laser scanning microscopy. The cellular uptake of GnRH-FITC conjugates was quantified by fluorescence-activated cell sorting. In these experiments minor differences among GnRH analogues and major differences among cell types was observed. The significant differences among cell lines are correlated with their distinct level of cell surface GnRH-I receptors. The introduced experiments contain practical methods to visualize, quantify and compare the uptake efficiency of GnRH-FITC conjugates in a time- and concentration-dependent manner on various adherent cell cultures. These results could predict the drug targeting efficiency of GnRH conjugates on the given cell culture, and offer a good basis for further experiments in the examination of GnRH-based drug delivery systems.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28362408      PMCID: PMC5409304          DOI: 10.3791/55529

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  16 in total

Review 1.  GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies.

Authors:  Patrizia Limonta; Marina Montagnani Marelli; Stefania Mai; Marcella Motta; Luciano Martini; Roberta M Moretti
Journal:  Endocr Rev       Date:  2012-07-09       Impact factor: 19.871

2.  Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.

Authors:  Ildikó Szabó; Szilvia Bősze; Erika Orbán; Éva Sipos; Gábor Halmos; Magdolna Kovács; Gábor Mező
Journal:  J Pept Sci       Date:  2015-04-24       Impact factor: 1.905

3.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

4.  Synthesis and in vitro evaluation of small-molecule [18F] labeled gonadotropin-releasing hormone (GnRH) receptor antagonists as potential PET imaging agents for GnRH receptor expression.

Authors:  Dag Erlend Olberg; Kjetil Wessel Andressen; Finn Olav Levy; Jo Klaveness; Ira Haraldsen; Julie L Sutcliffe
Journal:  Bioorg Med Chem Lett       Date:  2014-02-10       Impact factor: 2.823

5.  In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.

Authors:  Marilena Manea; József Tóvári; Miguel Tejeda; Akos Schulcz; Bence Kapuvári; Borbála Vincze; Gábor Mezo
Journal:  Anticancer Drugs       Date:  2012-01       Impact factor: 2.248

6.  A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging.

Authors:  Haixun Guo; Fabio Gallazzi; Larry A Sklar; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2011-07-23       Impact factor: 2.823

Review 7.  Hypothalamic hormones and cancer.

Authors:  A V Schally; A M Comaru-Schally; A Nagy; M Kovacs; K Szepeshazi; A Plonowski; J L Varga; G Halmos
Journal:  Front Neuroendocrinol       Date:  2001-10       Impact factor: 8.606

8.  Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.

Authors:  József Murányi; Pál Gyulavári; Attila Varga; Györgyi Bökönyi; Henriette Tanai; Tibor Vántus; Domonkos Pap; Krisztina Ludányi; Gábor Mező; György Kéri
Journal:  J Pept Sci       Date:  2016-08       Impact factor: 1.905

9.  Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.

Authors:  Orestis Argyros; Theodoros Karampelas; Xenophon Asvos; Aimilia Varela; Nisar Sayyad; Athanasios Papakyriakou; Constantinos H Davos; Andreas G Tzakos; Demosthenes Fokas; Constantin Tamvakopoulos
Journal:  Cancer Res       Date:  2015-12-08       Impact factor: 12.701

Review 10.  Gonadotropin-releasing hormone receptors.

Authors:  Robert P Millar; Zhi-Liang Lu; Adam J Pawson; Colleen A Flanagan; Kevin Morgan; Stuart R Maudsley
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.